2. Signaling Pathways
  3. Metabolic Enzyme/Protease
  4. Phosphatase

Phosphatase

Phosphatase

Related Products

PDF 2.61 MB

Phosphatases are enzyme that remove a phosphate group from a protein. Protein tyrosine phosphatases (PTPs) comprise a diverse family of transmembrane and cytoplasmic enzymes. PTPs play an important role in regulating the proliferative activity of cells and the integrity of cell-cell and cell-matrix contacts. Protein tyrosine phosphatase 1B (PTP1B) is a non-receptor PTP frequently associated with the endoplasmic reticulum and vesicles subjacent to the plasma membrane. PTP1B as a key negative regulator of leptin receptor pathways has been an attractive therapeutic target for the treatment of type 2 diabetes mellitus and obesity. Four major serine/threonine-specific protein phosphatase catalytic subunits are present in the cytoplasm of animal cells. Three of these enzymes, PP1, PP2A, and PP2B, are members of the same gene family, while PP2C appears to be distinct.The alkaline phosphatases comprise a heterogeneous group of enzymes that are widely distributed in mammalian cells. Acid phosphatase enzymes catalyze the hydrolysis of phosphate monoesters following the general equation.

Cat. No. Product Name Effect Purity Chemical Structure
  • HY-112800
    cyt-PTPε Inhibitor-1
    		Inhibitor 98.05%
    cyt-PTPε Inhibitor-1 is a potent cytosolic protein tyrosine phosphatase epsilon (cyt-PTPε) inhibitor, binds to the catalytic domain of cyt-PTPε, blocks c-Src activation (dephosphorylation of c-Src), and exhibits anti-osteoclastic activity.
    cyt-PTPε Inhibitor-1
  • HY-103265A
    ARL67156
    		Inhibitor
    ARL67156 is an inhibitor of ecto-ATPase. ARL 67156 is a weak competitive inhibitor of NTPDase1 (CD39), NTPDase3 and NPP1, with Kis of 11, 18 and 12 μM, respectively.
    ARL67156
  • HY-16309
    MB-07803
    		Inhibitor
    MB07803 is an orally available prodrug of a potent, noncompetitive inhibitor (MB07729) of fructose 1,6-bisphosphatase (FBPase), with EC50 of 140 nM and t1/2 of 7.6±2.9 h.
    MB-07803
  • HY-144718
    PTP1B-IN-17
    		Inhibitor
    PTP1B-IN-17 (Compound 45), a potential selective benzimidazole derivative, acts as a protein tyrosine phosphatase 1B (PTP1B) inhibitor with a Ki of 30.2 μM. PTP1B-IN-17 can be used for the research of type 2 diabetes.
    PTP1B-IN-17
  • HY-120159
    GS-493
    		Inhibitor
    GS-493 is a selective protein tyrosine phosphatase SHP2 (PTPN11) inhibitor with an IC50 of 71 nM. GS-493 is 29- and 45-fold more active toward SHP2 than related SHP1 and PTP1B. GS-493 blocks cellular motility and growth of cancer cells. Antitumor activity.
    GS-493
  • HY-P5441
    KRpTIRR
    KRpTIRR is a phosphothreonine-containing peptide and can serve as a substrate for phosphatases.
    KRpTIRR
  • HY-162119
    PRL-IN-1
    		Inhibitor
    PRL-IN-1 (compound 43) is a phosphatase of regenerating liver (PRL) inhibitor that directly binds the PRL1 trimer interface and obstructs PRL1 trimerization. PRL-IN-1 shows potent anticancer activities.
    PRL-IN-1
  • HY-160550
    DPM-1003
    		Inhibitor
    DPM-1003 is a PTP1B conformational inhibitor that targets the non-catalytic, disordered segment at the C-terminus of the PTP1B protein, showing improvement in lung inflammation in mice.
    DPM-1003
  • HY-162499
    MY17
    		Inhibitor
    MY17 is an inhibitor of protein tyrosine phosphatase 1B (PTP1B) (IC50=0.41±0.05 μM). MY17 alleviates palmitic acid (PA) -induced insulin resistance by up-regulating the expression of phosphorylated insulin receptor substrate (IRS1) and protein kinase B (AKT). By binding with PTP1B, MY17 can inhibit the activity of PTP1B, thereby improving insulin signaling and having anti-diabetic activity. MY17 can be used in the study of type 2 diabetes.
    MY17
  • HY-162478
    GR-28
    GR-28 is an inhibitor for small C-terminal domain phosphatase 1 (SCP1). GR-28 inhibits the transcriptional activity of repressor element-1 silencing transcription factor (REST), inhibits the proliferation of glioblastoma cells (IC50 is 2.9 and 10.1 µM, for cells A172 and T98G).
    GR-28
  • HY-P990267
    Anti-Mouse CD45RB Antibody (MB23G2)
    		Inhibitor
    Anti-Mouse CD45RB Antibody (MB23G2) is a rat-derived IgG2a κ type antibody inhibitor, targeting to mouse CD45RB. Anti-Mouse CD45RB Antibody (MB23G2) blocks CD45RB and induces transplantation tolerance. Anti-Mouse CD45RB Antibody (MB23G2) can be used for the researches of infection, immunology and metabolic disease, such as diabetes and Mem71 (H3N1) virus-infection.
    Anti-Mouse CD45RB Antibody (MB23G2)
  • HY-12312A
    TCS 401 free base
    		Inhibitor
    TCS 401 free base is a selective inhibitor of protein tyrosine phosphatase 1B (PTP1B).
    TCS 401 free base
  • HY-100167
    TAK-778
    		Agonist
    TAK-778 is a derivative of ipriflavone and has been shown to induce bone growth in in vitro and in vivo models.
    TAK-778
  • HY-163406
    PDE1-IN-6
    		Inhibitor
    PDE1-IN-6 (compound 6c) is a selectivity PDE1 inhibitor with the IC50 of 7.5 nM. PDE1-IN-6 significantly inhibits the proliferation and induced cell apoptosis in Acute myelogenous leukemia cells.
    PDE1-IN-6
  • HY-151591A
    SPAA-52 ammonium
    		Inhibitor
    SPAA-52 (ammonium) is a low molecular weight protein tyrosine phosphatase (LMW-PTP) inhibitor (IC50 = 4 nM; IC50 = 1.2 nM). SPAA-52 (ammonium) can be used in the research of diabetes mellitus.
    SPAA-52 ammonium
  • HY-173034
    PTP1B-IN-30
    		Inhibitor
    PTP1B-IN-30 (Compound 3j) is the inhibitor for PTP1B with an IC50 of 0.51 µM. PTP1B-IN-30 inhibits the proliferation of cancer cell T47D with an IC50 of 21.21 µM, arrests the cell cycle at S phase, and induces apoptosis in T47D.
    PTP1B-IN-30
  • HY-149942
    PAP-IN-1
    		Inhibitor
    PAP-IN-1 (compound 28) is an inhibitor of purple acid phosphatases (PAPs), a ubiquitous binuclear metallohydrolase. PAP-IN-1 inhibits mammalian PAP with Ki value of 168 nM. PAP-IN-1 targets to pig PAP with Kic value of 0.17 μM. PAP inhibitors can be used for research of anti-osteoporotic drugs.
    PAP-IN-1
  • HY-173084
    BRD6257
    		Inhibitor
    BRD6257 is an orally active inhibitor for protein phosphatase, Mg2+/Mn2+ dependent 1D PPM1D with an IC50 of 5 nM. BRD6257 activates p53 signaling pathway with an EC50 of 51 nM, increases the p21 expression, inhibits the proliferation of cancer cell MOLM13 (IC50=2.8 μM). BRD6257 exhibits good metabolic stability in human and rat liver microsomes.
    BRD6257
  • HY-135564
    RK-682 hemicalcium
    		Inhibitor
    RK-682 hemicalcium is the hemicalcium salt form of RK-682 (HY-135564A). RK-682 hemicalcium is the inhibitor for protein tyrosine phosphatase (PTPase), heparanase, phospholipase A2 and HIV-1 protease. RK-682 hemicalcium inhibits the dephosphorylation of CD45 (IC50 is 54 μM) and VHR (IC50 is 2.0 μM), and thereby inhibits the ERK signaling pathway. RK-682 hemicalcium inhibits the cell viability of cancer cell MGH-U3, T24 and UROtsa with IC50s of 78.2, 43.2 and 145 nM, respectively, arrests the cell cycle at G1/S phase, inhibits the cell migration and autophagy in MGH-U3 and T24[2].
    RK-682 hemicalcium
  • HY-149254
    PTP1B/AKR1B1-IN-1
    		Inhibitor
    PTP1B/AKR1B1-IN-1 is a dual inhibitor of protein tyrosine phosphatase 1B (PTP1B) and aldose reductase (AKR1B1), with IC50s of 0.06 μM and 4.3 μM, respectively. PTP1B/AKR1B1-IN-1 also inhibits TC-PTP with an IC50 value of 9 μM. PTP1B/AKR1B1-IN-1 serves as an insulin-mimetic agent in murine myoblasts, and reduces AKR1B1-dependent sorbitol accumulation. PTP1B/AKR1B1-IN-1 inhibits development of type 2 diabetes mellitus (T2DM) to control blood glucose levels.
    PTP1B/AKR1B1-IN-1
Cat. No. Product Name / Synonyms Species Source
Cat. No. Product Name / Synonyms Application Reactivity